EMEA-001220-PIP07-20
Key facts
| Invented name |
Olumiant
|
| Active substance |
Baricitinib
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0062/2021
|
| PIP number |
EMEA-001220-PIP07-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019
|
| Route(s) of administration |
|
| Contact for public enquiries |
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|